17 / 19
N
ETV %
HR (p)
CCR Kras (1)
172 (65 mut)
32.3/17.8
2.21 (1.08–4.53) (mut/wt)
NCSLC ALK+ (2,3,4)
241
55/43 (cohorte validación)
193
30
42/28
22,3
NSCLC ROS1 + (4)
95
34,7
Glioma podoplanina (5)
213
6,7(-)/14,6(+)/17,8 (++)/25,7
(+++)
5.71 (1.52-21.36) (p=0.010)
(+++/-)
Glioma IDH1 (6)
213
2,4 (mut)/17 (wt)
0.11 (0.01–0.80) (p = 0.029)
(mut/wt)
BIOMARCARDORES
1. Thromb Haemost 2015;13:998-1003
. 2.
Eur Respir J 2018; 51(5).
3.
Clin Lung Cancer 2017; 18:156-161
4.
J Thorac Oncol. 2018 Dec 10. [Epub ahead of print]
5.
Blood 2017;129:1831-1839.
6.
J Thromb Haemost.
2018;16:1121-1127.